Collaboration, License, and Other Agreements (Tables)

9 Months Ended

Sep. 30, 2022

Table Text Blocks

Schedule of revenue attributable to transactions from collaboration and license arrangements

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
Collaborative Arrangements Revenue	2022		2021		2022		2021
Linaclotide Collaboration and License Agreements:
AbbVie (North America)	$	106,085	$	101,061	$	296,047	$	288,598
AbbVie (Europe and other)		709		682		1,847		1,856
AstraZeneca (China, including Hong Kong and Macau)		144		219		484		629
Astellas (Japan)		520		555		1,543		1,621
Co-Promotion and Other Agreements:
Alnylam (GIVLAARI)		814		683		2,222		1,735
Other		365		547		1,254		1,359
Total collaborative arrangements revenue	$	108,637	$	103,747	$	303,397	$	295,798
Sale of API
Linaclotide Agreements:
AstraZeneca (China, including Hong Kong and Macau)	$	—	$	—	$	—	$	597
Other		—		—		—		228
Total sale of API	$	—	$	—	$	—	$	825

AbbVie

Table Text Blocks

Schedule of revenue attributable to transactions from collaboration and license arrangements

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2022		2021		2022		2021
Collaborative arrangements revenue related to sales of LINZESS in the U.S.	$	105,224	$	100,393	$	293,995	$	286,649
Royalty revenue		861		668		2,052		1,949
Total collaborative arrangements revenue	$	106,085	$	101,061	$	296,047	$	288,598